Clinical trial
Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic…
NCT00296400 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00296400 |
|---|---|
| Title | Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease |
| Official title | Randomised, Double-blind, 52-wk, Parallel-grp Multicentre, PIIb Study to Evaluate Effects of Rosuvastatin 10mg, Rosuvastatin 40mg and Atorvastatin 80mg on Urinary Protein Excretion in Hypercholesterolaemic Non-diabetic Patients With Moderate Proteinuria |
| Acronym | PLANET II |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hyperlipidemia |
| Intervention type | Drug |
| Interventions | Rosuvastatin, Atorvastatin |
| Enrollment | 237 |
| Start date | Feb 1, 2006 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Feb 27, 2006 |
| Last update posted | Jun 16, 2011 |
| Countries | Brazil, Bulgaria, Canada, Denmark, Germany, Hungary, Italy, Mexico, Romania, South Africa, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: